Protagonist Therapeutics, Inc.

NasdaqGM PTGX

Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -352.05 M

Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities is USD -352.05 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -1,455.90% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 25.96 M, a -77.50% change year over year.
Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 115.40 M, a 197.69% change year over year.
Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -118.13 M, a -305.70% change year over year.
Protagonist Therapeutics, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -29.12 M, a 20.46% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: PTGX

Protagonist Therapeutics, Inc.

CEO	Dr. Dinesh V. Patel Ph.D.
IPO Date	Aug. 11, 2016
Location	United States
Headquarters	7707 Gateway Boulevard
Employees	126
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Key trends

Past 5 years